Details
Stereochemistry | ACHIRAL |
Molecular Formula | C7H8ClN3O4S2 |
Molecular Weight | 297.739 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
InChI
InChIKey=JZUFKLXOESDKRF-UHFFFAOYSA-N
InChI=1S/C7H8ClN3O4S2/c8-4-1-5-7(2-6(4)16(9,12)13)17(14,15)11-3-10-5/h1-2,10-11H,3H2,(H2,9,12,13)
Molecular Formula | C7H8ClN3O4S2 |
Molecular Weight | 297.739 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1876 |
70.0 µM [IC50] | ||
Target ID: CHEMBL5742 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3037074 |
117.0 µM [IC50] |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
490 ng/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROCHLOROTHIAZIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
70 ng/mL |
12.5 mg 1 times / day steady-state, oral dose: 12.5 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
HYDROCHLOROTHIAZIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
142.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11112088/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: CAPTOPRIL |
HYDROCHLOROTHIAZIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
1032.22 ng/mL |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: CAPTOPRIL |
HYDROCHLOROTHIAZIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
164 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3034318/ |
25 mg 1 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered: CAPTOPRIL |
HYDROCHLOROTHIAZIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
210 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3034318/ |
25 mg 1 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered: CAPTOPRIL |
HYDROCHLOROTHIAZIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
954.44 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11112088/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: CAPTOPRIL |
HYDROCHLOROTHIAZIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
3615.08 ng × h/mL |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: CAPTOPRIL |
HYDROCHLOROTHIAZIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1629 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3034318/ |
25 mg 1 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered: CAPTOPRIL |
HYDROCHLOROTHIAZIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1760 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3034318/ |
25 mg 1 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered: CAPTOPRIL |
HYDROCHLOROTHIAZIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14.8 h |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROCHLOROTHIAZIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
8.57 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11112088/ |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: CAPTOPRIL |
HYDROCHLOROTHIAZIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
7.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3034318/ |
25 mg 1 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered: CAPTOPRIL |
HYDROCHLOROTHIAZIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
7.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3034318/ |
25 mg 1 times / day multiple, oral dose: 25 mg route of administration: Oral experiment type: MULTIPLE co-administered: CAPTOPRIL |
HYDROCHLOROTHIAZIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
46% |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROCHLOROTHIAZIDE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
56% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26142561/ |
HYDROCHLOROTHIAZIDE serum | Homo sapiens |
Doses
Dose | Population | Adverse events |
---|---|---|
50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 55.5 |
Disc. AE: Fatigue, Hypokalemia... AEs leading to discontinuation/dose reduction: Fatigue (1.12%) Sources: Hypokalemia (1.12%) Dry mouth (1.12%) |
100 mg single, oral Recommended Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Acute myopia, Angle closure glaucoma... AEs leading to discontinuation/dose reduction: Acute myopia Sources: Angle closure glaucoma |
50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Acute myopia, Angle closure glaucoma... AEs leading to discontinuation/dose reduction: Acute myopia Sources: Angle closure glaucoma Diabetes Hypoglycemia Renal disease |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dry mouth | 1.12% Disc. AE |
50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 55.5 |
Fatigue | 1.12% Disc. AE |
50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 55.5 |
Hypokalemia | 1.12% Disc. AE |
50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy, 55.5 |
Acute myopia | Disc. AE | 100 mg single, oral Recommended Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
Angle closure glaucoma | Disc. AE | 100 mg single, oral Recommended Dose: 100 mg Route: oral Route: single Dose: 100 mg Sources: |
unhealthy Health Status: unhealthy Sources: |
Acute myopia | Disc. AE | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Angle closure glaucoma | Disc. AE | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Diabetes | Disc. AE | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Hypoglycemia | Disc. AE | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Renal disease | Disc. AE | 50 mg 1 times / day multiple, oral Recommended Dose: 50 mg, 1 times / day Route: oral Route: multiple Dose: 50 mg, 1 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:53:04 GMT 2025
by
admin
on
Mon Mar 31 17:53:04 GMT 2025
|
Record UNII |
0J48LPH2TH
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EMA ASSESSMENT REPORTS |
RASITRIO (WITHDRAWN: HYPERTENSION)
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
TOLUCOMBI (AUTHORIZED: HYPERTENSION)
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
IBERSARTAN/HYDROCHLOROTHIAZIDE ZENTIVA (AUTHORIZED: HYPERTENSION)
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
||
|
WHO-ATC |
C03AB03
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
IBERSARTAN/HYDROCHLOROTHIAZIDE-BMS (WITHDRAWN: HYPERTENSION)
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
||
|
NDF-RT |
N0000166469
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
||
|
WHO-VATC |
QC09DX01
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
SPRIMEO-HCT (WITHDRAWN: HYPERTENSION)
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
EXFORGE-HCT (AUTHORIZED: HYPERTENSION)
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
||
|
WHO-VATC |
QC09DX03
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
KINZALKOMB (AUTHORIZED: HYPERTENSION)
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
KARVEZIDE (AUTHORIZED: HYPERTENSION)
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
||
|
WHO-ATC |
C09XA52
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
RASILEZ-HCT (AUTHORIZED: HYPERTENSION)
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
12.3
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
||
|
IARC | Hydrochlorothiazide | ||
|
EMA ASSESSMENT REPORTS |
IMPRIDA-HCT (WITHDRAWN: HYPERTENSION)
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
MICARDISPLUS (AUTHORIZED: HYPERTENSION)
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
||
|
WHO-ATC |
C03AA03
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
||
|
WHO-VATC |
QC03EA01
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
PRITORPLUS (AUTHORIZED: HYPERTENSION0
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
||
|
WHO-ATC |
C09XA54
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
||
|
WHO-VATC |
QC03AA03
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
||
|
WHO-ATC |
C03EA01
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
||
|
WHO-ATC |
C09DX01
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
||
|
WHO-ATC |
C09BX03
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
||
|
NDF-RT |
N0000175419
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
||
|
WHO-VATC |
QC09XA52
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
RIPRAZO-HCT (WITHDRAWN: HYPERTENSION)
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
12.4
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
||
|
WHO-VATC |
QC03AX01
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
||
|
LIVERTOX |
483
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
IBERSARTAN/HYDROCHLOROTHIAZIDE TEVA (AUTHORIZED: HYPERTENSION)
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
16
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
||
|
NDF-RT |
N0000175359
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
COPALIA-HCT (AUTHORIZED: HYPERTENSION)
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
||
|
WHO-VATC |
QC09XA54
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
IFIRMACOMBI (AUTHORIZED: HYPERTENSION)
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
||
|
WHO-VATC |
QC03AB03
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
||
|
CFR |
21 CFR 522.1150
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
||
|
WHO-ATC |
C09DX03
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
||
|
NDF-RT |
N0000166469
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
||
|
NCI_THESAURUS |
C49185
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
DAFIRO-HCT (AUTHORIZED: HYPERTENSION)
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
||
|
WHO-ATC |
C09DX06
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
||
|
WHO-ATC |
C03AX01
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
8049-49-8
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
SUPERSEDED | |||
|
DB00999
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
PRIMARY | |||
|
HYDROCHLOROTHIAZIDE
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
PRIMARY | |||
|
5487
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID2020713
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
PRIMARY | |||
|
HYDROCHLOROTHIAZIDE
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
PRIMARY | Description: A white or almost white, crystalline powder; odourless or almost odourless. Solubility: Very slightly soluble in water; practically insoluble in ether R; soluble in 200 parts of ethanol (~750 g/l) TS and in 20 parts of acetone R. Category: Diuretic. Storage: Hydrochlorothiazide should be kept in a well-closed container. Definition: Hydrochlorothiazide contains not less than 98.0% and not more than 102.0% of C7H8ClN3O4S2, calculated with reference to the dried substance. | ||
|
3096
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
PRIMARY | |||
|
58-93-5
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
PRIMARY | |||
|
1314009
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
PRIMARY | |||
|
100000091737
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
PRIMARY | |||
|
C29098
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
PRIMARY | |||
|
0J48LPH2TH
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
PRIMARY | |||
|
53477
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
PRIMARY | |||
|
D006852
Created by
admin on Mon Mar 31 17:53:04 GMT 2025 , Edited by admin on Mon Mar 31 17:53:04 GMT 2025
|
PRIMARY | |||
|
m6089
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
PRIMARY | Merck Index | ||
|
841
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
PRIMARY | |||
|
SUB08062MIG
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
PRIMARY | |||
|
Hydrochlorothiazide
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
PRIMARY | |||
|
3639
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
PRIMARY | |||
|
0J48LPH2TH
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
PRIMARY | |||
|
200-403-3
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
PRIMARY | |||
|
CHEMBL435
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
PRIMARY | |||
|
1385
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
PRIMARY | |||
|
4836
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
PRIMARY | |||
|
5778
Created by
admin on Mon Mar 31 17:53:05 GMT 2025 , Edited by admin on Mon Mar 31 17:53:05 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
EP
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
EXCRETED UNCHANGED |
URINE
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
TARGET -> INHIBITOR |
|
||
|
DERIVATIVE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||